SlideShare a Scribd company logo
SURVIVAL ANALYSIS
DR ATHAR KHAN
LIAQUAT COLLEGE OF MEDICINE & DENTISTRY
matharm@yahoo.com
4/20/2020 DR ATHAR KHAN 2
The surprising thing about young fools is how many
survive to become old fools.
—Doug Larson
4/20/2020 DR ATHAR KHAN 3
4/20/2020 DR ATHAR KHAN 4
Biomedical
Sciences
Engineering
Social
Sciences
4/20/2020 DR ATHAR KHAN 5
4/20/2020 DR ATHAR KHAN 6
4/20/2020 DR ATHAR KHAN 7
4/20/2020 DR ATHAR KHAN 8
4/20/2020 DR ATHAR KHAN 9
4/20/2020 DR ATHAR KHAN 10
4/20/2020 DR ATHAR KHAN 11
OUTCOME VARIABLE
4/20/2020 DR ATHAR KHAN 12
4/20/2020 DR ATHAR KHAN 13
4/20/2020 DR ATHAR KHAN 14
Case 2,4,6 are SE because they enter in the study
after the start of study but included in analysis
4/20/2020 DR ATHAR KHAN 15
4/20/2020 DR ATHAR KHAN 16
4/20/2020 DR ATHAR KHAN 17
Survival analysis, or more generally, time-to-event analysis,
refers to a set of methods for analyzing the length of time until
the occurrence of a well-defined end point of interest.
START
Time to event is outcome variable
Binary outcome (event has occurred versus it has not occurred)
EVENT
Death/Occurrence/Reoccurrence
/Survival after treatment
4/20/2020 DR ATHAR KHAN 18
TIME
Survival time, time-to-event, time to-
detection, failure time, relapse-free
survival time (also called disease-free survival
time), event-free survival.
Survival analysis is a statistical method which analyses data to
predict the time of occurrence of one or more event.
Survival time is time from the start of the study till the
occurrence of event is called survival time.
Survival in this context is remaining free of a particular outcome
over time.
Event-free survival which is the proportion of subjects who have
not yet experienced an event.
START EVENT
Complete remission/Relapse
4/20/2020 DR ATHAR KHAN 19
TIME
Survival time, time-to-event, event time, time
to-detection and failure time
Cancer Studies e.g. Leukemia patients [time in remission]
(weeks)
Disease-free cohort [time until heart disease] (years)
Elderly (60+) population [time until death] (years)
Heart transplants [time until death] (months)
START
The time to event or survival time can be measured in days,
weeks, years, etc.
EVENT
Death/Occurrence/Reoccurrence
/Survival after treatment
4/20/2020 DR ATHAR KHAN 20
TIME
Survival time, time-to-event, time to-
detection and failure time
Whether or not a participant suffers the event of interest during
the study period (i.e., a dichotomous variable) often coded as
1=event occurred or 0=event did not occur during the study
observation period.
Survival analysis focuses on two important pieces of information
4/20/2020 DR ATHAR KHAN 21
The follow up time for each individual being followed.
Follow Up Time: Time zero, or the time origin, is the time at
which participants are considered at-risk for the outcome of
interest.
4/20/2020 DR ATHAR KHAN 22
Types of Survival Analysis
▪ Non-parametric survival
▪ Kaplan-Meier method
▪ Life table method
▪ Nelson-Aalen method
▪ Parametric survival
▪ Exponential
▪ Weibull
▪ Gompertz
▪ Log-logistic
4/20/2020 DR ATHAR KHAN 23
Types of Survival Analysis
▪ Comparing survival distributions
▪ The log-rank test (also known as the Mantel log-rank test,
the Cox Mantel log-rank test, and the MantelHaenszel test)
is the most commonly used test for comparing survival
distributions.
▪ Breslow’s test (also known as Gehan’s generalised
Wilcoxon test)
4/20/2020 DR ATHAR KHAN 24
Types of Survival Analysis
▪ Survival models
▪ Survival models are used to quantify the effect of one or
more explanatory variables on failure time. This involves
specification of a linear-like model for the log hazard.
▪ Cox proportional hazards model
4/20/2020 DR ATHAR KHAN 25
Censoring
• Observations are called censored when the information
about their survival time is incomplete.
• There are three main types of censoring: right, left, and
interval.
• The most common is called right censoring.
• This can occur when a participant drops out before the
study ends (the participants observed time is less than the
length of the follow-up).
4/20/2020 DR ATHAR KHAN 26
Censoring
• When a participant is event free at the end of the
observation period (the participant's observed time is
equal to the length of the follow-up period).
4/20/2020 DR ATHAR KHAN 27
An observation is left-censored if its initial time at risk is unknown. This will
occur if we do not know when a participant experienced for the first time the
condition of interest. For example, when an individual contracted a disease.
4/20/2020 DR ATHAR KHAN 28
4/20/2020 DR ATHAR KHAN 29
INTERVAL CENSORING In many applications, the time of the
event may be known only up to a time interval, especially when
the time is established by periodical examinations
4/20/2020 DR ATHAR KHAN 30
4/20/2020 DR ATHAR KHAN 31
During the study period, three participants suffer myocardial infarction (MI), one
dies, two drop out of the study (for unknown reasons), and four complete the 10-
year follow-up without suffering MI.
4/20/2020 DR ATHAR KHAN 32
• An important assumption is made to make appropriate use
of the censored data. Specifically, we assume that
censoring is independent or unrelated to the likelihood of
developing the event of interest.
• This is called non-informative censoring and essentially
assumes that the participants whose data are censored
would have the same distribution of failure times (or times
to event) if they were actually observed.
4/20/2020 DR ATHAR KHAN 33
In survival analysis we analyze not only the numbers of participants who suffer
the event of interest (a dichotomous indicator of event status), but also the times
at which the events occur.
What is the likelihood that a participant will suffer an MI over 10
years? 3/10 = 30%
4/20/2020 DR ATHAR KHAN 34
4/20/2020 DR ATHAR KHAN 35
4/20/2020 DR ATHAR KHAN 36
4/20/2020 DR ATHAR KHAN 37
The Kaplan-Meier Assumptions
• The event status should consist of two mutually exclusive( 2
events cannot both occur at the same time) and collectively
exhaustive states (at least one of the events must occur)
• The event status is mutually exclusive because the outcome for
a case can either be censored or the event has occurred. It
cannot be both.
• The time to an event or censorship (known as the "survival
time") should be clearly defined and precisely measured.
4/20/2020 DR ATHAR KHAN 38
The Kaplan-Meier Assumptions
• Where possible, left-censoring should be minimized or
avoided.
• There should be independence of censoring and the event. This
means that the reason why cases are censored does not relate
to the event i.e. non informative censoring
• There should be a similar amount and pattern of censorship per
group.
4/20/2020 DR ATHAR KHAN 39
months 07 to 140 cutoff.
4/20/2020 DR ATHAR KHAN 40
4/20/2020 DR ATHAR KHAN 41
4/20/2020 DR ATHAR KHAN 42
4/20/2020 DR ATHAR KHAN 43
4/20/2020 DR ATHAR KHAN 44
4/20/2020 DR ATHAR KHAN 45
4/20/2020 DR ATHAR KHAN 46
Video Link
YouTube: How to Use SPSS-Kaplan-Meier Survival
Curve
https://www.youtube.com/watch?v=f4X5csxtJkE
4/20/2020 DR ATHAR KHAN 47
H o = normality
If you accept, then assume normality
If you reject, then do not assume normality
If p < then 0.05, reject the H0
Use Kaplan Meier Test
4/20/2020 DR ATHAR KHAN 48
▪ Overall censoring was 47/200(23.5%).
▪ Resumption of smoking was 153/200 (76.5%)
▪ Resumption of smoking in Hypnotherapy group was 79/104 (76%).
▪ Resumption of smoking in Nicotine patch group was 74/96(77%).
4/20/2020 DR ATHAR KHAN 49
4/20/2020 DR ATHAR KHAN 50
4/20/2020 DR ATHAR KHAN 51
▪ Mean resumption of smoking time was 60 ± 3 months.
▪ In group-HP, mean resumption time was 58.4 ± 4.31 months.
▪ On the other hand in group-NP, mean resumption time was
62.2 ± 4.2 months.
▪ Median resumption of smoking time was 46.8 months.
▪ In group-HP, median resumption time was 44.4 months.
▪ On the other hand in group-NP, median resumption time was
49.2 months.
4/20/2020 DR ATHAR KHAN 52
Confidence interval overlapping – No difference
22.6 75.7
35.7 51.2
Since there is a lot of overlap in the confidence intervals, it is unlikely that there is much
difference in the "average" survival time.
If confidence intervals do not overlap between levels, differences in effect on time to event
can be inferred.4/20/2020 DR ATHAR KHAN 53
Kaplan-Meier Survival Curve
4/20/2020 DR ATHAR KHAN 54
0.5
Median Survival
Time
▪ The horizontal axis shows the time to event.
▪ In this plot, drops in the survival curve occur whenever the
participant resume smoking.
▪ The vertical axis shows the probability of survival (probability
of resuming smoking).
▪ In survival analysis the survival probabilities are usually
reported at certain time points on the curve (e.g. 1 year and 5
year survival); otherwise the median survival time (the time at
which 50% of the subjects have reached the event) can be
reported.
4/20/2020 DR ATHAR KHAN 55
▪ Cumulative survival proportion appears to be higher in the
nicotine patch group compared to the hypnotherapy group.
▪ Hypnotherapy programme prolongs the time until participants
resume smoking (i.e., the event) compared to the other
interventions.
4/20/2020 DR ATHAR KHAN 56
Pancanology Explains Kaplan-Meier Graphs
https://www.youtube.com/watch?v=KE1tkZmWhqU
VIDEO
4/20/2020 DR ATHAR KHAN 57
▪ Survival curves cross each other (i.e., whether there is an
"interaction" between survival distributions).
▪ Survival curves are similarly shaped, even if they are above or
below one another.
▪ As such, a group survival curve that appears "above" another
group's survival curve is usually considered to be
demonstrating a beneficial/advantageous effect.
▪ Smooth curves are better than step down pattern curves.
4/20/2020 DR ATHAR KHAN 58
SMOOTH CURVE
4/20/2020 DR ATHAR KHAN 59
4/20/2020 DR ATHAR KHAN 60
4/20/2020 DR ATHAR KHAN 61
4/20/2020 DR ATHAR KHAN 62
The p-value (sig) is the probability of getting a test statistic of at
least 0.379 if there really is no difference in survival times for
treatment groups. As the p-value = 0.538 and is greater than 0.05,
conclude that there is no significant evidence of a difference in
survival times for treatment groups. The estimated time until
resumption is 44.4 months for HP and 49.2 months for NP this
difference is statistically NOT significant (p=0.538) therefore,
both groups have similar time for start of smoking again.
4/20/2020 DR ATHAR KHAN 63
The log rank test
▪ The log-rank test tests the hypothesis that there is no difference
in survival times between the groups studied at all time points in
the study.
▪ The log rank rest for the data in our example was P = 0.538;
thus the two curves are not statistically significantly different.
4/20/2020 DR ATHAR KHAN 64
▪ Log-rank test: what happens later in time.
▪ Breslow: what happens later in time.
▪ Tarone: what happens middle in time.
▪ All three test p-value <0.05 – significant results
▪ All three test p-value > 0.05 – insignificant results
▪ If mix – at certain points significant
4/20/2020 DR ATHAR KHAN 65
KM CURVE EXAMPLES
4/20/2020 DR ATHAR KHAN 66
4/20/2020 DR ATHAR KHAN 67
4/20/2020 DR ATHAR KHAN 68
4/20/2020 DR ATHAR KHAN 69
4/20/2020 DR ATHAR KHAN 70
4/20/2020 DR ATHAR KHAN 71
ONE GROUP
4/20/2020 DR ATHAR KHAN 72
4/20/2020 DR ATHAR KHAN 73
EXERCISE
4/20/2020 DR ATHAR KHAN 74
4/20/2020 DR ATHAR KHAN 75
4/20/2020 DR ATHAR KHAN 76
4/20/2020 DR ATHAR KHAN 77
REFERENCES
• http://sphweb.bumc.bu.edu/otlt/MPH-
Modules/BS/BS704_Survival/BS704_Survival_print.html
• https://statistics.laerd.com/spss-tutorials/kaplan-meier-using-
spss-statistics.php
4/20/2020 DR ATHAR KHAN 78
4/20/2020 DR ATHAR KHAN 79
4/20/2020 DR ATHAR KHAN 80
DR ATHAR KHAN
MBBS, MCPS, DPH, DCPS-HCSM, DCPS-HPE, MBA, PGD-
STATISTICS, CCRP
ASSOCIATE PROFESSOR
DEPARTMENT OF COMMUNITY MEDICINE
LIAQUAT COLLEGE OF MEDICINE & DENTISTRY
KARACHI, PAKISTAN
0092-3232135932

More Related Content

What's hot

SURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.pptSURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.ppt
mbang ernest
 
Survival Analysis Using SPSS
Survival Analysis Using SPSSSurvival Analysis Using SPSS
Survival Analysis Using SPSS
Nermin Osman
 
Survival Analysis
Survival AnalysisSurvival Analysis
Survival Analysis
SMAliKazemi
 
Survival analysis
Survival analysisSurvival analysis
Survival analysis
Har Jindal
 
SURVIVAL ANALYSIS 1.pptx
SURVIVAL ANALYSIS 1.pptxSURVIVAL ANALYSIS 1.pptx
SURVIVAL ANALYSIS 1.pptx
DrVikasKaushik1
 
Survival Analysis Lecture.ppt
Survival Analysis Lecture.pptSurvival Analysis Lecture.ppt
Survival Analysis Lecture.ppt
habtamu biazin
 
Introduction To Survival Analysis
Introduction To Survival AnalysisIntroduction To Survival Analysis
Introduction To Survival Analysis
federicorotolo
 
Odds ratio
Odds ratioOdds ratio
Odds ratio
Madhur Bora
 
Overview on randomized control trial
Overview on randomized control trial Overview on randomized control trial
Overview on randomized control trial
Nouran Hamza, MSc, PgDPH
 
Application of survival data analysis introduction and discussion
Application of survival data analysis  introduction and discussionApplication of survival data analysis  introduction and discussion
Application of survival data analysis introduction and discussion
ASQ Reliability Division
 
Life Tables & Kaplan-Meier Method.pptx
 Life Tables & Kaplan-Meier Method.pptx Life Tables & Kaplan-Meier Method.pptx
Life Tables & Kaplan-Meier Method.pptx
Pravin Kolekar
 
Case control study
Case control studyCase control study
Case control study
Dr. Adrija Roy
 
Randomized Controlled Trial
Randomized Controlled TrialRandomized Controlled Trial
Randomized Controlled Trial
Govt Medical College, Surat.
 
What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean? What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean?
Terry Shaneyfelt
 
Epidemiology lecture3 incidence
Epidemiology lecture3 incidenceEpidemiology lecture3 incidence
Epidemiology lecture3 incidence
INAAMUL HAQ
 
Estimating risk
Estimating riskEstimating risk
Estimating risk
Tarek Tawfik Amin
 
ODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATIONODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATION
Kanhu Charan
 
Cox model
Cox modelCox model
Cox model
Veronica Navia
 

What's hot (20)

SURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.pptSURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.ppt
 
Survival Analysis Using SPSS
Survival Analysis Using SPSSSurvival Analysis Using SPSS
Survival Analysis Using SPSS
 
Survival Analysis
Survival AnalysisSurvival Analysis
Survival Analysis
 
Survival analysis
Survival analysisSurvival analysis
Survival analysis
 
SURVIVAL ANALYSIS 1.pptx
SURVIVAL ANALYSIS 1.pptxSURVIVAL ANALYSIS 1.pptx
SURVIVAL ANALYSIS 1.pptx
 
Survival Analysis Lecture.ppt
Survival Analysis Lecture.pptSurvival Analysis Lecture.ppt
Survival Analysis Lecture.ppt
 
Introduction To Survival Analysis
Introduction To Survival AnalysisIntroduction To Survival Analysis
Introduction To Survival Analysis
 
Odds ratio
Odds ratioOdds ratio
Odds ratio
 
Overview on randomized control trial
Overview on randomized control trial Overview on randomized control trial
Overview on randomized control trial
 
Part 2 Cox Regression
Part 2 Cox RegressionPart 2 Cox Regression
Part 2 Cox Regression
 
Application of survival data analysis introduction and discussion
Application of survival data analysis  introduction and discussionApplication of survival data analysis  introduction and discussion
Application of survival data analysis introduction and discussion
 
Life Tables & Kaplan-Meier Method.pptx
 Life Tables & Kaplan-Meier Method.pptx Life Tables & Kaplan-Meier Method.pptx
Life Tables & Kaplan-Meier Method.pptx
 
Case control study
Case control studyCase control study
Case control study
 
Randomized Controlled Trial
Randomized Controlled TrialRandomized Controlled Trial
Randomized Controlled Trial
 
What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean? What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean?
 
Epidemiology lecture3 incidence
Epidemiology lecture3 incidenceEpidemiology lecture3 incidence
Epidemiology lecture3 incidence
 
Estimating risk
Estimating riskEstimating risk
Estimating risk
 
ODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATIONODDS RATIO AND RELATIVE RISK EVALUATION
ODDS RATIO AND RELATIVE RISK EVALUATION
 
Randomization
Randomization Randomization
Randomization
 
Cox model
Cox modelCox model
Cox model
 

Similar to Survival analysis & Kaplan Meire

A gentle introduction to survival analysis
A gentle introduction to survival analysisA gentle introduction to survival analysis
A gentle introduction to survival analysis
Angelo Tinazzi
 
6 Epidemiologic Study Designs feke.ppptx
6 Epidemiologic Study Designs feke.ppptx6 Epidemiologic Study Designs feke.ppptx
6 Epidemiologic Study Designs feke.ppptx
yisihakchalachew
 
LoveJ-SurvivalAnalysis to analyse degreee completion.pptx
LoveJ-SurvivalAnalysis to analyse degreee completion.pptxLoveJ-SurvivalAnalysis to analyse degreee completion.pptx
LoveJ-SurvivalAnalysis to analyse degreee completion.pptx
TroyTeo1
 
Experimental study design.pptx
Experimental study design.pptxExperimental study design.pptx
Experimental study design.pptx
Dr. Chirag Sonkusare
 
Cohort, case control & survival studies-2014
Cohort, case control & survival studies-2014Cohort, case control & survival studies-2014
Cohort, case control & survival studies-2014
Ramnath Takiar
 
IS IT ENDING OF START ERA
IS IT ENDING OF START ERAIS IT ENDING OF START ERA
IS IT ENDING OF START ERA
Kanhu Charan
 
Journal Club: 2015 August; START study
Journal Club: 2015 August; START studyJournal Club: 2015 August; START study
Journal Club: 2015 August; START study
Sri Lanka College of Sexual Health and HIV Medicine
 
Study Designs Cohort StudiesChapter 7Learning.docx
Study Designs Cohort StudiesChapter 7Learning.docxStudy Designs Cohort StudiesChapter 7Learning.docx
Study Designs Cohort StudiesChapter 7Learning.docx
deanmtaylor1545
 
Cohort Studies by Dr. Mohammed Jawad 2020
Cohort Studies by Dr. Mohammed Jawad 2020Cohort Studies by Dr. Mohammed Jawad 2020
Cohort Studies by Dr. Mohammed Jawad 2020
Kadium
 
Randomized Controlled Trials
Randomized Controlled TrialsRandomized Controlled Trials
Randomized Controlled Trials
Nabeela Basha
 
Epidemiology Lectures for UG
Epidemiology Lectures for UGEpidemiology Lectures for UG
Epidemiology Lectures for UG
amitakashyap1
 
What is survival analysis, and when should I use it?
What is survival analysis, and when should I use it?What is survival analysis, and when should I use it?
What is survival analysis, and when should I use it?
Cecilia M. Patino-Sutton, MD MeD PhD
 
Study Design - Retrospective cohort study
Study Design - Retrospective cohort studyStudy Design - Retrospective cohort study
Study Design - Retrospective cohort study
Dr.Bharat Kalidindi
 
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUMEFEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
Kanhu Charan
 
Cohort study
Cohort studyCohort study
Cohort study
Dr. Ankit Gaur
 
Module5_Study_Design.pptx
Module5_Study_Design.pptxModule5_Study_Design.pptx
Module5_Study_Design.pptx
ShafaatHussain20
 
B04621019
B04621019B04621019
B04621019
IOSR-JEN
 
Research Methods in Health Sciences
Research Methods in Health SciencesResearch Methods in Health Sciences
Research Methods in Health Sciences
Dr Arindam Basu
 
Resrach hypothesis
Resrach hypothesisResrach hypothesis
Resrach hypothesis
Tarek Tawfik Amin
 
semo2037
semo2037semo2037
semo2037
memomemo87
 

Similar to Survival analysis & Kaplan Meire (20)

A gentle introduction to survival analysis
A gentle introduction to survival analysisA gentle introduction to survival analysis
A gentle introduction to survival analysis
 
6 Epidemiologic Study Designs feke.ppptx
6 Epidemiologic Study Designs feke.ppptx6 Epidemiologic Study Designs feke.ppptx
6 Epidemiologic Study Designs feke.ppptx
 
LoveJ-SurvivalAnalysis to analyse degreee completion.pptx
LoveJ-SurvivalAnalysis to analyse degreee completion.pptxLoveJ-SurvivalAnalysis to analyse degreee completion.pptx
LoveJ-SurvivalAnalysis to analyse degreee completion.pptx
 
Experimental study design.pptx
Experimental study design.pptxExperimental study design.pptx
Experimental study design.pptx
 
Cohort, case control & survival studies-2014
Cohort, case control & survival studies-2014Cohort, case control & survival studies-2014
Cohort, case control & survival studies-2014
 
IS IT ENDING OF START ERA
IS IT ENDING OF START ERAIS IT ENDING OF START ERA
IS IT ENDING OF START ERA
 
Journal Club: 2015 August; START study
Journal Club: 2015 August; START studyJournal Club: 2015 August; START study
Journal Club: 2015 August; START study
 
Study Designs Cohort StudiesChapter 7Learning.docx
Study Designs Cohort StudiesChapter 7Learning.docxStudy Designs Cohort StudiesChapter 7Learning.docx
Study Designs Cohort StudiesChapter 7Learning.docx
 
Cohort Studies by Dr. Mohammed Jawad 2020
Cohort Studies by Dr. Mohammed Jawad 2020Cohort Studies by Dr. Mohammed Jawad 2020
Cohort Studies by Dr. Mohammed Jawad 2020
 
Randomized Controlled Trials
Randomized Controlled TrialsRandomized Controlled Trials
Randomized Controlled Trials
 
Epidemiology Lectures for UG
Epidemiology Lectures for UGEpidemiology Lectures for UG
Epidemiology Lectures for UG
 
What is survival analysis, and when should I use it?
What is survival analysis, and when should I use it?What is survival analysis, and when should I use it?
What is survival analysis, and when should I use it?
 
Study Design - Retrospective cohort study
Study Design - Retrospective cohort studyStudy Design - Retrospective cohort study
Study Design - Retrospective cohort study
 
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUMEFEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
 
Cohort study
Cohort studyCohort study
Cohort study
 
Module5_Study_Design.pptx
Module5_Study_Design.pptxModule5_Study_Design.pptx
Module5_Study_Design.pptx
 
B04621019
B04621019B04621019
B04621019
 
Research Methods in Health Sciences
Research Methods in Health SciencesResearch Methods in Health Sciences
Research Methods in Health Sciences
 
Resrach hypothesis
Resrach hypothesisResrach hypothesis
Resrach hypothesis
 
semo2037
semo2037semo2037
semo2037
 

More from Dr Athar Khan

Growth Chart, GROWTH MONITORING, MALNUTRITION
Growth Chart,  GROWTH MONITORING, MALNUTRITIONGrowth Chart,  GROWTH MONITORING, MALNUTRITION
Growth Chart, GROWTH MONITORING, MALNUTRITION
Dr Athar Khan
 
Rheumatic heart disease
Rheumatic heart disease Rheumatic heart disease
Rheumatic heart disease
Dr Athar Khan
 
Prevention of Hypertension
Prevention of Hypertension Prevention of Hypertension
Prevention of Hypertension
Dr Athar Khan
 
Reference writing
Reference writing Reference writing
Reference writing
Dr Athar Khan
 
Item Analysis, Difficulty Index, Discrimination Index,ExamAnalysis
Item Analysis, Difficulty Index, Discrimination Index,ExamAnalysisItem Analysis, Difficulty Index, Discrimination Index,ExamAnalysis
Item Analysis, Difficulty Index, Discrimination Index,ExamAnalysis
Dr Athar Khan
 
Genomics Genetics Community Public Health
Genomics Genetics Community Public Health Genomics Genetics Community Public Health
Genomics Genetics Community Public Health
Dr Athar Khan
 
Ethics Professionalism
Ethics Professionalism Ethics Professionalism
Ethics Professionalism
Dr Athar Khan
 
Professionalism Ethics
Professionalism EthicsProfessionalism Ethics
Professionalism Ethics
Dr Athar Khan
 
Critical thinking analysis skills
Critical thinking analysis skillsCritical thinking analysis skills
Critical thinking analysis skills
Dr Athar Khan
 
Health System
Health SystemHealth System
Health System
Dr Athar Khan
 
Causation of Disease
Causation of DiseaseCausation of Disease
Causation of Disease
Dr Athar Khan
 
Environmental Health
Environmental HealthEnvironmental Health
Environmental Health
Dr Athar Khan
 
Introduction to Environmental Health
Introduction to Environmental HealthIntroduction to Environmental Health
Introduction to Environmental Health
Dr Athar Khan
 
Who is an author ? Authorship Criteria
Who is an author ? Authorship CriteriaWho is an author ? Authorship Criteria
Who is an author ? Authorship Criteria
Dr Athar Khan
 
Writing Introduction Background Literature Review
Writing Introduction Background Literature ReviewWriting Introduction Background Literature Review
Writing Introduction Background Literature Review
Dr Athar Khan
 
Searching for literature review
Searching for literature reviewSearching for literature review
Searching for literature review
Dr Athar Khan
 
How to read a scientific paper
How to read a scientific paperHow to read a scientific paper
How to read a scientific paper
Dr Athar Khan
 
Selection of Topic for Research
Selection of Topic  for ResearchSelection of Topic  for Research
Selection of Topic for Research
Dr Athar Khan
 
Healthcare care waste management
Healthcare care waste managementHealthcare care waste management
Healthcare care waste management
Dr Athar Khan
 
Ergonomics
ErgonomicsErgonomics
Ergonomics
Dr Athar Khan
 

More from Dr Athar Khan (20)

Growth Chart, GROWTH MONITORING, MALNUTRITION
Growth Chart,  GROWTH MONITORING, MALNUTRITIONGrowth Chart,  GROWTH MONITORING, MALNUTRITION
Growth Chart, GROWTH MONITORING, MALNUTRITION
 
Rheumatic heart disease
Rheumatic heart disease Rheumatic heart disease
Rheumatic heart disease
 
Prevention of Hypertension
Prevention of Hypertension Prevention of Hypertension
Prevention of Hypertension
 
Reference writing
Reference writing Reference writing
Reference writing
 
Item Analysis, Difficulty Index, Discrimination Index,ExamAnalysis
Item Analysis, Difficulty Index, Discrimination Index,ExamAnalysisItem Analysis, Difficulty Index, Discrimination Index,ExamAnalysis
Item Analysis, Difficulty Index, Discrimination Index,ExamAnalysis
 
Genomics Genetics Community Public Health
Genomics Genetics Community Public Health Genomics Genetics Community Public Health
Genomics Genetics Community Public Health
 
Ethics Professionalism
Ethics Professionalism Ethics Professionalism
Ethics Professionalism
 
Professionalism Ethics
Professionalism EthicsProfessionalism Ethics
Professionalism Ethics
 
Critical thinking analysis skills
Critical thinking analysis skillsCritical thinking analysis skills
Critical thinking analysis skills
 
Health System
Health SystemHealth System
Health System
 
Causation of Disease
Causation of DiseaseCausation of Disease
Causation of Disease
 
Environmental Health
Environmental HealthEnvironmental Health
Environmental Health
 
Introduction to Environmental Health
Introduction to Environmental HealthIntroduction to Environmental Health
Introduction to Environmental Health
 
Who is an author ? Authorship Criteria
Who is an author ? Authorship CriteriaWho is an author ? Authorship Criteria
Who is an author ? Authorship Criteria
 
Writing Introduction Background Literature Review
Writing Introduction Background Literature ReviewWriting Introduction Background Literature Review
Writing Introduction Background Literature Review
 
Searching for literature review
Searching for literature reviewSearching for literature review
Searching for literature review
 
How to read a scientific paper
How to read a scientific paperHow to read a scientific paper
How to read a scientific paper
 
Selection of Topic for Research
Selection of Topic  for ResearchSelection of Topic  for Research
Selection of Topic for Research
 
Healthcare care waste management
Healthcare care waste managementHealthcare care waste management
Healthcare care waste management
 
Ergonomics
ErgonomicsErgonomics
Ergonomics
 

Recently uploaded

Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
chandankumarsmartiso
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
MGM SCHOOL/COLLEGE OF NURSING
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 

Recently uploaded (20)

Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 

Survival analysis & Kaplan Meire

  • 1. SURVIVAL ANALYSIS DR ATHAR KHAN LIAQUAT COLLEGE OF MEDICINE & DENTISTRY matharm@yahoo.com
  • 2. 4/20/2020 DR ATHAR KHAN 2 The surprising thing about young fools is how many survive to become old fools. —Doug Larson
  • 4. 4/20/2020 DR ATHAR KHAN 4 Biomedical Sciences Engineering Social Sciences
  • 11. 4/20/2020 DR ATHAR KHAN 11 OUTCOME VARIABLE
  • 14. 4/20/2020 DR ATHAR KHAN 14 Case 2,4,6 are SE because they enter in the study after the start of study but included in analysis
  • 18. Survival analysis, or more generally, time-to-event analysis, refers to a set of methods for analyzing the length of time until the occurrence of a well-defined end point of interest. START Time to event is outcome variable Binary outcome (event has occurred versus it has not occurred) EVENT Death/Occurrence/Reoccurrence /Survival after treatment 4/20/2020 DR ATHAR KHAN 18 TIME Survival time, time-to-event, time to- detection, failure time, relapse-free survival time (also called disease-free survival time), event-free survival.
  • 19. Survival analysis is a statistical method which analyses data to predict the time of occurrence of one or more event. Survival time is time from the start of the study till the occurrence of event is called survival time. Survival in this context is remaining free of a particular outcome over time. Event-free survival which is the proportion of subjects who have not yet experienced an event. START EVENT Complete remission/Relapse 4/20/2020 DR ATHAR KHAN 19 TIME Survival time, time-to-event, event time, time to-detection and failure time
  • 20. Cancer Studies e.g. Leukemia patients [time in remission] (weeks) Disease-free cohort [time until heart disease] (years) Elderly (60+) population [time until death] (years) Heart transplants [time until death] (months) START The time to event or survival time can be measured in days, weeks, years, etc. EVENT Death/Occurrence/Reoccurrence /Survival after treatment 4/20/2020 DR ATHAR KHAN 20 TIME Survival time, time-to-event, time to- detection and failure time
  • 21. Whether or not a participant suffers the event of interest during the study period (i.e., a dichotomous variable) often coded as 1=event occurred or 0=event did not occur during the study observation period. Survival analysis focuses on two important pieces of information 4/20/2020 DR ATHAR KHAN 21 The follow up time for each individual being followed. Follow Up Time: Time zero, or the time origin, is the time at which participants are considered at-risk for the outcome of interest.
  • 23. Types of Survival Analysis ▪ Non-parametric survival ▪ Kaplan-Meier method ▪ Life table method ▪ Nelson-Aalen method ▪ Parametric survival ▪ Exponential ▪ Weibull ▪ Gompertz ▪ Log-logistic 4/20/2020 DR ATHAR KHAN 23
  • 24. Types of Survival Analysis ▪ Comparing survival distributions ▪ The log-rank test (also known as the Mantel log-rank test, the Cox Mantel log-rank test, and the MantelHaenszel test) is the most commonly used test for comparing survival distributions. ▪ Breslow’s test (also known as Gehan’s generalised Wilcoxon test) 4/20/2020 DR ATHAR KHAN 24
  • 25. Types of Survival Analysis ▪ Survival models ▪ Survival models are used to quantify the effect of one or more explanatory variables on failure time. This involves specification of a linear-like model for the log hazard. ▪ Cox proportional hazards model 4/20/2020 DR ATHAR KHAN 25
  • 26. Censoring • Observations are called censored when the information about their survival time is incomplete. • There are three main types of censoring: right, left, and interval. • The most common is called right censoring. • This can occur when a participant drops out before the study ends (the participants observed time is less than the length of the follow-up). 4/20/2020 DR ATHAR KHAN 26
  • 27. Censoring • When a participant is event free at the end of the observation period (the participant's observed time is equal to the length of the follow-up period). 4/20/2020 DR ATHAR KHAN 27
  • 28. An observation is left-censored if its initial time at risk is unknown. This will occur if we do not know when a participant experienced for the first time the condition of interest. For example, when an individual contracted a disease. 4/20/2020 DR ATHAR KHAN 28
  • 30. INTERVAL CENSORING In many applications, the time of the event may be known only up to a time interval, especially when the time is established by periodical examinations 4/20/2020 DR ATHAR KHAN 30
  • 32. During the study period, three participants suffer myocardial infarction (MI), one dies, two drop out of the study (for unknown reasons), and four complete the 10- year follow-up without suffering MI. 4/20/2020 DR ATHAR KHAN 32
  • 33. • An important assumption is made to make appropriate use of the censored data. Specifically, we assume that censoring is independent or unrelated to the likelihood of developing the event of interest. • This is called non-informative censoring and essentially assumes that the participants whose data are censored would have the same distribution of failure times (or times to event) if they were actually observed. 4/20/2020 DR ATHAR KHAN 33
  • 34. In survival analysis we analyze not only the numbers of participants who suffer the event of interest (a dichotomous indicator of event status), but also the times at which the events occur. What is the likelihood that a participant will suffer an MI over 10 years? 3/10 = 30% 4/20/2020 DR ATHAR KHAN 34
  • 38. The Kaplan-Meier Assumptions • The event status should consist of two mutually exclusive( 2 events cannot both occur at the same time) and collectively exhaustive states (at least one of the events must occur) • The event status is mutually exclusive because the outcome for a case can either be censored or the event has occurred. It cannot be both. • The time to an event or censorship (known as the "survival time") should be clearly defined and precisely measured. 4/20/2020 DR ATHAR KHAN 38
  • 39. The Kaplan-Meier Assumptions • Where possible, left-censoring should be minimized or avoided. • There should be independence of censoring and the event. This means that the reason why cases are censored does not relate to the event i.e. non informative censoring • There should be a similar amount and pattern of censorship per group. 4/20/2020 DR ATHAR KHAN 39
  • 40. months 07 to 140 cutoff. 4/20/2020 DR ATHAR KHAN 40
  • 47. Video Link YouTube: How to Use SPSS-Kaplan-Meier Survival Curve https://www.youtube.com/watch?v=f4X5csxtJkE 4/20/2020 DR ATHAR KHAN 47
  • 48. H o = normality If you accept, then assume normality If you reject, then do not assume normality If p < then 0.05, reject the H0 Use Kaplan Meier Test 4/20/2020 DR ATHAR KHAN 48
  • 49. ▪ Overall censoring was 47/200(23.5%). ▪ Resumption of smoking was 153/200 (76.5%) ▪ Resumption of smoking in Hypnotherapy group was 79/104 (76%). ▪ Resumption of smoking in Nicotine patch group was 74/96(77%). 4/20/2020 DR ATHAR KHAN 49
  • 52. ▪ Mean resumption of smoking time was 60 ± 3 months. ▪ In group-HP, mean resumption time was 58.4 ± 4.31 months. ▪ On the other hand in group-NP, mean resumption time was 62.2 ± 4.2 months. ▪ Median resumption of smoking time was 46.8 months. ▪ In group-HP, median resumption time was 44.4 months. ▪ On the other hand in group-NP, median resumption time was 49.2 months. 4/20/2020 DR ATHAR KHAN 52
  • 53. Confidence interval overlapping – No difference 22.6 75.7 35.7 51.2 Since there is a lot of overlap in the confidence intervals, it is unlikely that there is much difference in the "average" survival time. If confidence intervals do not overlap between levels, differences in effect on time to event can be inferred.4/20/2020 DR ATHAR KHAN 53
  • 54. Kaplan-Meier Survival Curve 4/20/2020 DR ATHAR KHAN 54 0.5 Median Survival Time
  • 55. ▪ The horizontal axis shows the time to event. ▪ In this plot, drops in the survival curve occur whenever the participant resume smoking. ▪ The vertical axis shows the probability of survival (probability of resuming smoking). ▪ In survival analysis the survival probabilities are usually reported at certain time points on the curve (e.g. 1 year and 5 year survival); otherwise the median survival time (the time at which 50% of the subjects have reached the event) can be reported. 4/20/2020 DR ATHAR KHAN 55
  • 56. ▪ Cumulative survival proportion appears to be higher in the nicotine patch group compared to the hypnotherapy group. ▪ Hypnotherapy programme prolongs the time until participants resume smoking (i.e., the event) compared to the other interventions. 4/20/2020 DR ATHAR KHAN 56
  • 57. Pancanology Explains Kaplan-Meier Graphs https://www.youtube.com/watch?v=KE1tkZmWhqU VIDEO 4/20/2020 DR ATHAR KHAN 57
  • 58. ▪ Survival curves cross each other (i.e., whether there is an "interaction" between survival distributions). ▪ Survival curves are similarly shaped, even if they are above or below one another. ▪ As such, a group survival curve that appears "above" another group's survival curve is usually considered to be demonstrating a beneficial/advantageous effect. ▪ Smooth curves are better than step down pattern curves. 4/20/2020 DR ATHAR KHAN 58
  • 59. SMOOTH CURVE 4/20/2020 DR ATHAR KHAN 59
  • 63. The p-value (sig) is the probability of getting a test statistic of at least 0.379 if there really is no difference in survival times for treatment groups. As the p-value = 0.538 and is greater than 0.05, conclude that there is no significant evidence of a difference in survival times for treatment groups. The estimated time until resumption is 44.4 months for HP and 49.2 months for NP this difference is statistically NOT significant (p=0.538) therefore, both groups have similar time for start of smoking again. 4/20/2020 DR ATHAR KHAN 63
  • 64. The log rank test ▪ The log-rank test tests the hypothesis that there is no difference in survival times between the groups studied at all time points in the study. ▪ The log rank rest for the data in our example was P = 0.538; thus the two curves are not statistically significantly different. 4/20/2020 DR ATHAR KHAN 64
  • 65. ▪ Log-rank test: what happens later in time. ▪ Breslow: what happens later in time. ▪ Tarone: what happens middle in time. ▪ All three test p-value <0.05 – significant results ▪ All three test p-value > 0.05 – insignificant results ▪ If mix – at certain points significant 4/20/2020 DR ATHAR KHAN 65
  • 66. KM CURVE EXAMPLES 4/20/2020 DR ATHAR KHAN 66
  • 72. ONE GROUP 4/20/2020 DR ATHAR KHAN 72
  • 80. 4/20/2020 DR ATHAR KHAN 80 DR ATHAR KHAN MBBS, MCPS, DPH, DCPS-HCSM, DCPS-HPE, MBA, PGD- STATISTICS, CCRP ASSOCIATE PROFESSOR DEPARTMENT OF COMMUNITY MEDICINE LIAQUAT COLLEGE OF MEDICINE & DENTISTRY KARACHI, PAKISTAN 0092-3232135932